P3 Health Partners agrees to sell up to $70 million of preferred stock units with warrants in private placement

P3 Health Partners entered a securities purchase agreement on Sept. 8, 2026 for up to $70 million of unregistered units.

• Units include Series D-1 19.5% cumulative preferred stock, issued in multiple tranches with a $100 stated value per share.
• Warrants accompany the preferred stock, exercisable for Class A shares equal to 0.66333% of outstanding Class A and Class V per $1 million funded.
• Warrants carry a seven-year term with an exercise price set at the Nasdaq Minimum Price on the issuance date.
• The company agreed to file a resale registration statement for warrant shares, subject to any Nasdaq-required stockholder approval.